Stoke Therapeutics, Inc (STOK)

Etorro trading 970x250
Stoke Therapeutics, Inc (STOK) Logo

About Stoke Therapeutics, Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Address: 45 Wiggins Avenue, Bedford, MA, United States, 01730

Stoke Therapeutics, Inc News and around…

Latest news about Stoke Therapeutics, Inc (STOK) common stock and company :

61 Biggest Movers From Yesterday
23 Nov, 2021 FinancialContent

Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the ...

12 Health Care Stocks Moving In Monday's Intraday Session
22 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading ...

40 Stocks Moving In Monday's Mid-Day Session
22 Nov, 2021 FinancialContent

Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to ...

Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
22 Nov, 2021 FinancialContent

Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:KIM) was changed from In-Line to ...

Stoke Therapeutics Gets JPMorgan Upgrade
22 Nov, 2021 Yahoo! Finance

By Sam Boughedda

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting
19 Nov, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that five abstracts related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual Meeting, taking place December 3 – 7, 2021 in Chicago.

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
08 Nov, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of 2021 and provided business updates.

Notable Stoke Therapeutics Insider Trades $150K In Company Stock
04 Nov, 2021 Yahoo! Finance

Huw Nash, COO And Cbo at Stoke Therapeutics (NASDAQ:STOK), made a large buy and sell of company shares on November 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Huw Nash exercised options to purchase 5,700 Stoke Therapeutics shares at a price of $2.19 per share for a total of $12,483 on November 3. They then sold their shares on succeeding transactions in the open market. They sold at prices ranging from $23.41 to $2

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
03 Nov, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at two upcoming investor conferences in November.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
06 Oct, 2021 FinancialContent

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular ...

Look Under The Hood: LABU Has 71% Upside
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $94.28 per unit.

Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference
22 Sep, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference on Tuesday, September 28, 2021, at 4:00 p.m. ET.

Stoke Therapeutics Posts Encouraging Interim Safety Data From Early-Stage Dravet Syndrome Trial
21 Sep, 2021 FinancialContent

Stoke Therapeutics Inc(NASDAQ: STOK)announced interim analysis datafrom Phase 1/2a MONARCH study of STK-001 in ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
21 Sep, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data from a planned interim analysis of the multi-center, open-label Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. STK-001 is an investigational new medicine for the treatment of Dravet syndrome. As part of today’s announcement, the company is providing several updates on the clinical progress of STK-001. Management will host a webinar and conference call today at 8:30 a.m. Eastern Time.

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
13 Sep, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

How The Pieces Add Up: WDNA Targets $35
30 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $34.94 per unit.

Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
17 Aug, 2021 FinancialContent

Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
10 Aug, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the second quarter of 2021 and provided business updates.

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stoke Therapeutics to Present at Upcoming Investor Conferences in August
03 Aug, 2021 FinancialContent

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences in August.

Stoke Therapeutics is Now Oversold (STOK)
27 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Peek Under The Hood: WDNA Has 28% Upside
28 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree BioRevolution Fund ETF (WDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $34.01 per unit.

Stoke Therapeutics, Inc (STOK) is a NASDAQ Common Stock listed in , ,

970x250